Franklin, Parlapiano, Turner & Welch’s Novo Nordisk NVO Stock Holding History

Franklin, Parlapiano, Turner & Welch’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-880	Closed	-$15K	–	91
2017 Q1	$15K	Hold	880	–	–	0.01%	101
2016 Q4	$16K	Hold	880	–	–	0.01%	98
2016 Q3	$18K	Hold	880	–	–	0.01%	93
2016 Q2	$24K	Hold	880	–	–	0.01%	85
2016 Q1	$24K	Hold	880	–	–	0.01%	85
2015 Q4	$26K	Buy	+880	New	+$24.4K	0.02%	85

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return

Franklin, Parlapiano, Turner & Welch's NVO Position: Q2 2017 in Review

Franklin, Parlapiano, Turner & Welch sold out of Novo Nordisk (NVO) in Q2 2017, closing a stake of 880 shares — an estimated $15K sold.

Franklin, Parlapiano, Turner & Welch first reported a position in NVO in Q4 2015 and held it in 6 quarters. The position peaked at $26K in Q4 2015. 484 funds tracked by Wall St. Rank hold NVO as of Q2 2017.

Franklin, Parlapiano, Turner & Welch reported no remaining Novo Nordisk position as of Q2 2017 after selling out during the quarter.
Franklin, Parlapiano, Turner & Welch sold 880 Novo Nordisk shares in Q2 2017, an estimated $15K.
Franklin, Parlapiano, Turner & Welch first reported a position in Novo Nordisk in Q4 2015 and held it in 6 quarters.
Franklin, Parlapiano, Turner & Welch's Novo Nordisk position peaked at $26K in Q4 2015.
484 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2017.

Based on Franklin, Parlapiano, Turner & Welch's 13F filing for Q2 2017, filed 17 Jul 2017.